Loading clinical trials...

COMPLETEDPHASE3

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease

NCT00434148•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years or greater
•Confirmed diagnosis of ACTH-dependent Cushing's disease
•Not considered candidate for pituitary surgery

Exclusion Criteria

•History of pituitary irradiation in the last 10 years
•Cushing's syndrome not caused by pituitary tumor
•Patients with active malignant disease (cancer) in the last 5 years
•Women who are pregnant or lactating

Locations (68)

Stanford University Medical Center Stanford Cancer Center (3)

Stanford, California, United States

University Chicago Hospital Dept. of Univ of Chicago

Chicago, Illinois, United States

Dana Farber Cancer Institute The Melanoma Program

Boston, Massachusetts, United States

Columbia University Medical Center- New York Presbyterian Columbia University DeptofMed

New York, New York, United States

Cleveland Clinic Foundation Dept. of Cleveland Clinic (6)

Cleveland, Ohio, United States

Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU.

Portland, Oregon, United States

University of Texas Southwestern Medical Center Clinical-TranslationalRes.Ctr.

Dallas, Texas, United States

University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(8)

Houston, Texas, United States

Baylor College of Medicine

Houston, Texas, United States

Swedish Medical Center Dept.ofSeattle Neuroscience(2)

Seattle, Washington, United States

Key Dates

Start Date

December 1, 2006

Primary Completion Date

March 1, 2010

Completion Date

May 1, 2014

Last Updated

March 8, 2016

Enrollment

162

ACTUAL participants

Conditions

Cushing's Disease

Interventions

Pasireotide

DRUG

DDAVP for Pituitary Adenoma

NCT04569591

Cushing's DiseasePituitary Adenoma

View study

COMPLETEDNA

Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease

NCT03346954

Cushing's Disease

View study

COMPLETEDPHASE3

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 8, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions